In a troubling revelation, internal records have surfaced showing that top officials from the Trump administration’s Environmental Protection Agency (EPA) convened with Bayer’s CEO, Bill Anderson, to discuss legal strategies concerning the company’s glyphosate-based herbicides, including Roundup. This meeting, held on 17 June 2025, took place just months before the administration undertook actions perceived as favourable to Bayer’s ongoing legal battles against claims linking glyphosate to cancer.
Meeting Details and Implications
The pivotal meeting involved Anderson and two other senior Bayer executives, alongside key EPA figures, including Lee Zeldin, the agency’s administrator. According to planning emails uncovered through a Freedom of Information Act request, the agenda explicitly included discussions on “supreme court action” and litigation strategies. Bayer faces a multitude of lawsuits from individuals who assert that the company failed to adequately warn them about the cancer risks associated with glyphosate use.
Bayer’s approach to mitigating these extensive legal challenges hinges on persuading the Supreme Court to adopt its argument that it cannot be held liable for failing to issue cancer warnings if the EPA does not mandate such warnings on their products. While one appellate court has sided with Bayer, other courts have dismissed this preemption argument, including the Biden administration’s solicitor general.
Political Influence and Corporate Interests
Environmental advocates have expressed alarm over the apparent collusion between Bayer and government regulators. Nathan Donley, from the Center for Biological Diversity, articulated concerns about the prioritisation of corporate profits over public health. “It’s becoming abundantly clear that the political appointees at the EPA are more invested in protecting pesticide company profits than the health of Americans,” he stated. This sentiment underscores a growing unease regarding the influence of major corporations in shaping environmental regulations and public health policy.
Since the meeting, the Trump administration has taken multiple steps to bolster Bayer’s position in its legal battles. In December, the administration’s solicitor general recommended that the Supreme Court hear Bayer’s case, a request that the court subsequently granted. Furthermore, the White House invoked the Defense Production Act to safeguard the production of glyphosate and offer immunity to its manufacturers, including Bayer.
Criticism from Legal Experts and Activists
Legal experts and advocates for public health have raised significant concerns regarding the implications of such high-level meetings. Whitney Di Bona, an attorney focused on consumer safety, highlighted the troubling nature of a major pesticide company’s CEO being granted private discussions with the EPA. “We should also ask whether the agency gave the same chance to speak to the thousands of people who say they got cancer after using Roundup,” she remarked.
This scenario exemplifies a broader issue: the disparity in access to government officials between corporate entities and the general public. Naomi Oreskes, a Harvard professor and corporate regulation analyst, noted that such interactions often reveal a pattern of industry leaders receiving preferential treatment, while ordinary citizens are left unheard.
Zen Honeycutt, founder of Moms Across America, echoed these sentiments, stating that the influence of chemical companies over regulatory bodies is a longstanding concern. “Coercion by chemical companies on our regulatory agencies is nothing new,” she asserted, indicating that efforts by grassroots organisations to engage with the EPA have yielded minimal results.
Why it Matters
This situation is emblematic of a troubling trend in the intersection of corporate interests and public health policy. As the Trump administration appears to align itself with Bayer in the ongoing glyphosate litigation, the health and safety of countless Americans hang in the balance. The implications extend beyond this case, raising critical questions about the integrity of regulatory processes and the extent to which corporate power can shape environmental policies. As citizens demand accountability and transparency, the need for robust protections against corporate influence in health matters has never been more urgent.
